Mazindol

Global Narcolepsy Drugs Market Research Report 2024: Pipeline Analysis, Key Company Profiles and Recent Developments 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 30, 2024
General Health, Pharmaceutical, Health, Narcolepsy, Jazz Pharmaceuticals, CIII, FDA, Central nervous system, Somnolence, Consciousness, Quality of life, DSM-IV codes, Mazindol, Takeda Pharmaceutical Company, Tobacco, Organization, Cataplexy, EDS, Prevalence, American Academy, CNS, Selective serotonin reuptake inhibitor, Growth, Patient, Diagnosis, Marketing, Disease, U.S. FDA, NINDS, Research, Therapy, Teva Pharmaceuticals, Investment, Avadel Pharmaceuticals, European Medicines Agency, Pharmaceutical industry

The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global narcolepsy drugs market has witnessed significant growth in recent years owing to the rising prevalence of narcolepsy and increased awareness about the condition.
  • Latin America and Middle East & Africa are competing closely to grab the maximum share of the global narcolepsy drugs market.
  • Global Narcolepsy Drugs Market - Key Company Profiles, Recent Developments, Financial Insights

Narcolepsy Drugs Market, Size, Global Forecast 2024-2030: Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023
Health, Pharmaceutical, Novartis, Teva Pharmaceuticals, Quality of life, Sodium oxybate, Food, Risk, Drug development, Takeda Pharmaceutical Company, Roche, Research, Cataplexy, FDA, Instability, Prevalence, NINDS, Incidence, Mazindol, GHB, Stimulant, EDS, NMPA, Narcolepsy, Tobacco, DSM-IV codes, Investment, Patient, Diagnosis, Organization, Somnolence, Neurological disorder, Pharmaceutical industry

The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Narcolepsy Drugs Market is poised for substantial growth, with a projected value of US$5.95 billion by 2030
    Several factors contribute to the expansion of the narcolepsy drugs market.
  • The Narcolepsy Drugs Market is expected to grow steadily, with a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030.
  • Combined, these elements make the U.S. narcolepsy drugs market a leader in global healthcare.

NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating Narcolepsy

Retrieved on: 
Tuesday, May 18, 2021
Psychoactive drugs, Branches of biology, Molecular neuroscience, Neuroscience, Stimulants, Sleep disorders, Neuropeptides, Chloroarenes, Orexin, Mazindol, Reuptake inhibitor, Narcolepsy

Narcolepsy is caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.

Key Points: 
  • Narcolepsy is caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.
  • NLS believes that the new data also support prior in-vitro data from studies conducted by the Company demonstrating the partial binding affinity of mazindol to OX2R, which NLS believes is a key pathway that mediates mazindol\'s stimulant-like effects.
  • We believe that Quiliencewill provide a differentiated solution in this treatment category given mazindol\'s dual mechanism of action, namely orexin pathway activation and pan-monoaminergic reuptake inhibition in the brain.
  • NLS completed a Phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD.

NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)

Retrieved on: 
Wednesday, May 5, 2021
Psychoactive drugs, Amphetamine, Stimulants, Chloroarenes, Imidazolines, Mazindol, Narcolepsy, Attention deficit hyperactivity disorder, Drug

EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "Earlier this year, we were granted a similar patent in Canada, and our U.S. patent application is pending review.
  • Additionally, this newly issued patent augments the Orphan Drug Designations that we have for Quilience in both Europe and the U.S.
  • The Company\'s lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

Retrieved on: 
Monday, March 29, 2021
Psychoactive drugs, Amphetamine, Stimulants, Chloroarenes, Sleep disorders, Imidazolines, Mazindol, Narcolepsy, Attention deficit hyperactivity disorder

3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • 3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "We are very pleased to have obtained the first patent covering our novel formulation of controlled-release mazindol as we advance the development of Quilience to treat narcolepsy and other potential sleep-wake disorders," said Alex Zwyer, Chief Executive Officer of NLS.
  • "Our application for a similar patent in Europe received notice of allowance in January, and our U.S. patent application is pending review.
  • The Company's lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

NLS Pharmaceutics Ltd. Announces Notice of Allowance of a New Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy

Retrieved on: 
Thursday, January 21, 2021
Intellectual property law, Psychoactive drugs, Canadian patent law, Canadian intellectual property law, Childhood psychiatric disorders, Psychiatric diagnosis, Canadian Intellectual Property Office, Canadian trademark law, Attention deficit hyperactivity disorder, CIPO, Attention deficit, Mazindol

On November 23, 2020, the Canadian Intellectual Property Office (CIPO) issued a similar notice of allowance for the counterpart Canadian application.

Key Points: 
  • On November 23, 2020, the Canadian Intellectual Property Office (CIPO) issued a similar notice of allowance for the counterpart Canadian application.
  • NLS awaits the impending grant of the European and Canadian patents.
  • 17724102, entitled "A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)", has been examined and allowed for issuance as a patent by the EPO on January 21, 2021.
  • This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws.

Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy

Retrieved on: 
Monday, January 13, 2020
Biotechnology, Pharmaceutical, Health, Psychoactive drugs, Drugs, Stimulants, TAAR1 agonists, Norepinephrine reuptake inhibitor, Mazindol, Aptalis, Reuptake inhibitor, Adare, NLS

Adare Pharmaceuticals, Inc. (Adare) and NLS Pharmaceutics Ltd. (NLS) announced today a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).

Key Points: 
  • Adare Pharmaceuticals, Inc. (Adare) and NLS Pharmaceutics Ltd. (NLS) announced today a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).
  • MZD is a norepinephrine reuptake inhibitor previously approved by the U.S. Food and Drug Administration for the treatment of obesity.
  • Our expertise with product development and manufacturing of customized release and multiparticulate dosage forms makes this an ideal partnership for Adare.
  • Adare Pharmaceuticals utilizes its differentiated Pharmaceutical Technology and Microbiome scientific platforms to develop novel value-added products for the global market.